Interferon-alfa treatment reduces the risk of hepatic events particularly among responders to treatment.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: